Hospitals are turning to synthetic data—artificially generated datasets that mimic real patient data—to work around privacy constraints, enable AI development, and simulate clinical trials. Recent reviews and frameworks emphasize that synthetic data must be judged along three main dimensions: fidelity (how well it resembles real data), utility (how well it supports intended analyses or models), and privacy/confidentiality (risk of re-identification or leakage of real patients) [1][2][3][4]. New scorecards and evaluation frameworks tailored to medical synthetic data now provide practical guidance for hospitals [4][5].

Key Factors

1. Define “fit for purpose” before evaluating

Hospitals should start by defining the intended use case, because “good enough” differs between:

• AI/ML development (e.g., training a sepsis prediction model)

• Methods development (trying new analytic pipelines)

• Education and simulation (resident training, mock registries)

• Regulatory-facing analyses (synthetic control arms in trials, safety signal exploration) [2][6].

For each project, specify:

• Clinical domain (e.g., oncology, ICU, rare disease).

• Critical endpoints (mortality, readmission, lab thresholds).

• Acceptable error margins versus real data (e.g., AUC within 0.03 of real-world baseline, prevalence within ±10%).

This “context for use” aligns with emerging “scorecard” frameworks that emphasize Context and Control as the first dimensions when judging synthetic medical data [4].

2. Assess statistical fidelity and clinical plausibility

Hospitals should use a two-layer fidelity assessment:

a) Statistical similarity to source data
Use multivariate metrics highlighted in recent synthetic-data evaluation frameworks [1][3][7]:

• Distributional similarity: Kolmogorov–Smirnov tests, Earth Mover’s Distance, correlation structure comparison.

• Higher-order structure:

• Joint distributions of key variables (e.g., comorbidities vs. age vs. medications).

• Temporal patterns for longitudinal data (e.g., lab trends around admission).

• Global “fidelity scores” combining multiple metrics, as proposed in holistic frameworks for synthetic tabular health data [1][3].

b) Clinical face validity
Even statistically close data can be clinically nonsensical (e.g., impossible lab combinations). Hospitals should:

• Run rule-based clinical checks (e.g., vital-sign ranges, lab compatibilities, treatment sequences).

• Have domain experts review:

• Representative patient trajectories.

• Outliers and edge cases.

• Subgroups (e.g., pediatrics, pregnancy, advanced CKD).

Evidence from a scorecard for synthetic medical data suggests that combining statistical congruence with clinical expert review (“Congruence” plus “Curation”) is key to trustworthiness [4].

3. Validate analytic and AI utility

Fidelity alone is insufficient; hospitals must show that synthetic data supports the same conclusions and models as real data. Recent work on high‑fidelity synthetic EHRs and “digital twin” cohorts shows that well‑generated data can replicate prediction performance closely if properly evaluated [2][3][7].

Recommended steps:

1. Model-transfer tests

• Train model A on real data, test on real vs. synthetic.

• Train model B on synthetic data, test on held‑out real data.

• Compare AUC, calibration, sensitivity/specificity, and decision thresholds.

1. Replicate key analyses

• Re-run primary statistical analyses (e.g., regression estimates, hazard ratios) on synthetic vs. real cohorts.

• Compare effect sizes, confidence intervals, and p‑value concordance (e.g., >80–90% concordance in direction and significance).

1. Edge-case / subgroup utility

• Inspect performance in rare subgroups (e.g., rare mutations, extreme ages) where synthetic generators often underperform.

Recent frameworks stress balancing fidelity–privacy–utility trade‑offs: moderate fidelity with preserved causal structure often produces better downstream performance than maximum fidelity that risks leakage [3][7].

4. Rigorously assess privacy and re‑identification risk

Synthetic data does not automatically guarantee anonymity. Reviews in 2024–2026 emphasize the need for explicit privacy risk quantification [1][3][7]:

Key actions:

• Membership inference / linkage tests:

• Estimate whether an attacker could infer if a real patient was in the training data.

• Record linkage tests:

• Try to match synthetic records back to real patients using quasi‑identifiers (age, sex, ZIP, rare diagnoses).

• Differential privacy or controlled noise:

• For high‑risk domains (rare diseases, very small cohorts), require formal privacy protections or intentional noise injection.

HIPAA updates for 2025 make security controls (encryption, MFA, audit trails) fully mandatory rather than “addressable,” and introduce expectations around AI explainability and auditability for data pipelines [8][9]. Hospitals should treat synthetic data as regulated health data inside their perimeter and:

• Apply the same technical safeguards as for de‑identified EHRs (encryption, access controls, logging).

• Treat cross‑border sharing under GDPR/EDPB 2026 research guidance as potentially involving “personal data” if re‑identification risk is non‑negligible [10].

5. Institutional governance: IRB, ethics, and documentation

Recent guidance and commentaries emphasize creating a formal governance layer for synthetic data:

• IRB/Ethics review

• If synthetic data are generated entirely from de‑identified sources and no re‑contact or intervention occurs, many studies qualify as non-human-subjects research or IRB‑exempt [5][11].

• However, when synthetic data are used to support clinical decision tools, clinical trials, or regulatory submissions, IRBs and ethics committees expect clear documentation of generation, evaluation, and limitations [10][11].

• Standardized documentation / “Synthetic Data Dossier” (aligned with the 7 Cs scorecard [4]):

• Context: use case, clinical domain, intended decisions.

• Capacity: data sources, sample sizes, generator class (e.g., GAN, VAE, LLM‑based, rule-based).

• Curation: preprocessing, feature engineering, handling of missingness.

• Congruence / Consistency: fidelity metrics, clinical plausibility checks, stability across random seeds.

• Confidence: summary of utility tests and performance gaps vs. real data.

• Confidentiality: privacy metrics, linkage tests, DP parameters if used.

• Control: governance, access controls, monitoring and versioning.

• Regulatory alignment

• The FDA’s 2025 AI guidance for drug and biologic submissions expects explicit justification whenever AI-generated or synthetic data support regulatory decisions, with transparency around data provenance and model lifecycle [6].

• A 2026 pharma‑oriented acceptance‑criteria guide emphasizes clear thresholds on fidelity, utility, and privacy before synthetic data are considered “fit‑for‑use” in regulated settings [6].

6. Continuous monitoring and updating

Synthetic data quality is not static. As hospital case mix, coding, and practice patterns change, the training data underlying synthetic generators become outdated. Best practice from recent reviews is to:

• Time‑stamp every synthetic dataset with source data interval and generator version.

• Re-generate and re‑validate on a schedule (e.g., annually or when major coding or workflow changes occur).

• Continuously monitor downstream model performance (drift, calibration, subgroup bias) and trace issues back to underlying synthetic vs. real data.

Counterarguments & Limitations

• “Synthetic means safe” is false; high‑fidelity models can leak sensitive patterns if training data are too small or not well anonymized.

• Overconfidence in synthetic-only pipelines can yield fragile models that fail when confronted with messy real-world data.

• For rare events and causal inference, several recent studies caution that synthetic data may under-represent important edge cases unless specifically tuned, making real‑data validation essential [1][2][3].

Implications for Hospitals

An actionable hospital strategy should include:

1. Policy: A written synthetic data policy that defines use cases, minimal evaluation requirements, and approval workflows.

2. Technical standards: A shared evaluation toolkit (fidelity/utility/privacy metrics, scorecard template) embedded in the data science environment.

3. Governance: A multi‑disciplinary synthetic data review group (data science, clinicians, privacy/compliance, IRB liaison) that signs off on high‑impact uses (e.g., clinical AI).

4. Education: Training for clinicians and researchers on interpreting and reporting synthetic data, including explicit limitations.

Taken together, this positions synthetic data as a powerful but carefully governed asset, not a shortcut around rigorous data stewardship.